Presented by Z . Jafari MSc in Medical Biotechnology of ... · • PET imaging uses...
Transcript of Presented by Z . Jafari MSc in Medical Biotechnology of ... · • PET imaging uses...
-
Presented by Z . Jafari
MSc in Medical Biotechnology of QUMS
Supervisor : Dr. Ahmad pour
05/23/2017
1
-
Overview Introductions
Methods and techniques
Discussion
References2
-
Contents Introduction of cellular imaging modalities……..……………………………………..…………………….....…...6
The principle of cell Tracking with MRI…......……9
Cancer tracking and MRI Direct cell labeling techniques.............................11
Indirect cell labeling techniques……………………..12
Limitation of indirect cell labeling techniques....16
Encapsulation cell labeling techniques..…………..18
Statistic …………………………………………….…………..19
Articles………………………………………………...…...….21
References ……………..………………………….………..54
3
Cancer tracking
-
contentsIntroduction…….…………………………………………….……………….27
The principal of Pet CT imaging…….………………….....…………..28
Radiotracer of Pet CT……………………………….……………….…....29
Mechanism of radiotracer like FDG..……………......................30
Which cancer we can use FDG? ……………………………….….….32
30-deoxy-30-18F-fluorothymidine (FLT)……….……….………..33
FMAU…………………………………………………….……………….…....34
PET radiotracers have been developed to image hypoxia…....35
Cancer tracking with PET CT Imaging Apoptosis…………………………………….…………...………….……...37
The second class of imaging agents targets caspases…………..………...38
A third class of imaging agents……………………………….….……..39
References ……………………………………………………………….….…56
4Cancer tracking
-
Introduction………..………………………………………………………………….43
Cancer tracking and immunology Cytotoxic T lymphocytes and cell labeling method…..…………….…...45
And bioluminescence and optical Tracking T cells by optical fluorescence and bioluminescence imaging
Fleurcence imaging direct labeling methods…………………………………………………………….46
Indirect labeling methods…………………………………………………….……47
Articles……………………………………………………………………………………51
references…………………………………………………………………………….…57
5
Contents:
-
6
cellular Imaging modalities
introduction
Cancer tracking
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297829/figure/ijms-18-00198-f002/
-
7
discussion
in vivo
-
8
The principle of cell Tracking with MRI
The indirect cell labeling techniques
introduction
Cancer tracking
-
9
The direct cell labeling techniques
Cells(for cancer issues dendritic cells , T cells
cancer immunotherapy and cancer properties MSCs ) are incubated with an MRI contrast
agent in vitro and prior to transplantation , with a
transfection agent such as PLL or lipofectamine
Cancer tracking
-
10
The direct cell labeling techniques
Endogen exogen
Entrance of CA PinocytosisPhagocytosisWith sonicationelectroporation
CA ( MNP , paramagnetic , Gd , SPIONs superparamagnetic iron oxidate np)to macrophage
The way of labeling Targeting the cell surface receptors with antibody conjugated MRI CA ortargeting phagocytic nature of endogenous cell population
Like endogen
limitation Yes for the difficulty of isolating the neural stem cell because they are sub ventricular zone
It can’t distinguish between live and death cells 1:the differences T1and T2 of CA in live and death cells 2:effect of PH which usually with death cells
-
11
The direct cell labeling techniques
Cancer tracking
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297829/figure/ijms-18-00198-f003/
-
12
The indirect cell labeling techniques
Cells transfected with transfection agents or transduced with viral vectors to express an MRI reporter gene.
A Reporter gene is a gene that can fused to a gene of interest or cloned after that expression of it can create a peptide, protein Nano structure receptor or enzymatic activation to generate an MRI contrast
Cancer tracking
-
13
Cancer tracking
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297829/figure/ijms-18-00198-f003/
-
14
The indirect cell labeling techniques
Advantage of the
indirect technique
s
Use genetically engineering
Engineered cells proliferate to
generate daughter cells
MRI signal is not diluted
Live labeled cells distinguished
from dead cells
The reporter gene is expressed only in live cells and switched off in
dead cells
Cancer tracking
-
15
Examples of MRI
reporter gene
systems
Iron _binding receptor transferrin (that require T2/T2* MRI contrast agent )
The iron storage protein ferritin (that require T2/T2* MRI contrast agent )
The_ βgalactosidase which hydrolysis of β _D _ galactosidases(the require T1 MRI contrast agent like Gd )
Reporter genes which use CEST contrast generation mechanism such as :LRP(lysine rich protein)or HSV1
The indirect cell labeling techniques
Cancer tracking
-
16
-use of imaging agents with unfavorable pharmacokinetic profile lead to a delayed MRI signal and then result in false negative low sensitivity of reporter genes by biological function lead to low detection_developed reporter gen in bacterial origins non human origins _usually reporter genes are immunogenic
Limitation of indirect cell labeling techniques:
Cancer tracking
-
17
The encapsulation cell labeling Technique
_Use of biomaterials : such as alginate capsules to protect therapeutic cells from immune cells and permit the diffusion of small molecular weight such as water and nutrients_ polycations such as :PLL(poly _L _ lysine)to control pore sizes-Therapeutic cells and MRI agents are encapsulated together in vitro prior to transplantation
Cancer tracking
-
18
The encapsulation cell labeling Technique
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297829/figure/ijms-18-00198-f003/
-
Statistic in cancer tracking between 2000-2017 years
19
2000-2004 2004-2008 2008-2012 2012-2016 2016-2017
تعداد مقاالت 44300 66900 106000 59700 34300
44300
66900
106000
59700
34300
0
20000
40000
60000
80000
100000
120000
140000
Ar
tic
les
years
Cancer tracking
-
Cancer tracking with mri
20
2000-2004 2004-2008 2008-2012 2012-2016 2016-2017
Series1 5270 13500 18100 17900 9590
5270
13500
18100 17900
9590
0
5000
10000
15000
20000
25000
Art
icle
s
years
cancer tracking with mri
Cancer tracking
-
21
Discussion
in vivo
https://www.ncbi.nlm.nih.gov/pubmed/25625023
-
22
invitro
Discussion
https://www.ncbi.nlm.nih.gov/pubmed/27030399
-
23
discussion
invitro
https://www.ncbi.nlm.nih.gov/pubmed/23813415
-
24
discussion
in vivo
https://www.ncbi.nlm.nih.gov/pubmed/24523059
-
25
Cancer tracking with pet CT
Cancer tracking
-
26
https://www.ncbi.nlm.nih.gov/pubmed/24947987
-
27
PET- CT(positron emission computed tomography)
• Pet CT is a type of nuclear medicine imaging• Nuclear medicine is a branch of medical imaging
that uses small amounts of radioactive material to detect severity or treat diseases include many type of cancers heart diseases , neurological disorder endocrine and gastrointestinal • Because nuclear medicine procedure able pinpoint
molecular activity within the body
Cancer tracking
https://image.slidesharecdn.com/medicalimaging-130804074029-phpapp01/95/medical-imaging-overview-21-638.jpg?cb=1375602411
introduction
-
28
the principals of pet CT imaging
• PET imaging uses radiopharmaceuticals (or radiotracers like DG( deoxy glucose )and … labeled with positron emitting radioisotopes such as 11C, 13N, 15O, and 18F,which are produced in a cyclotron which are produced in a radioisotope generator.
• the positron annihilates and generates 2 annihilation photons (each with an energy of 511 k eV),which travel in opposite directions.
• PET scanners are equipped with coincidence electronics to detect these pairs of photons as they hit opposing detectors
Cancer tracking
-
30
Radiotracer of PET CT
Cancer tracking
https://www.ncbi.nlm.nih.gov/pubmed/24947987
-
31
the mechanism of radiotracers like FDG
• Radiotracers in PET/CT allows to quantify the metabolic activity of a tumor (like glycolysis) and become a reference tool in oncology for the tissue staging ,radiotherapy planning and monitoring response in many cancers.
• In 18 F- fluorodeoxyglucose (18F-FDG) is transported into cells in parallel with glucose and is phosphorylated with hexokinase to F_deoxyglycose-6-phosphate because lack of a hydroxyl group at the 2 position , it’s prevented from being a substrate of enzymes farther down the glycolytic pathway
• FDG_6_phosphate trapped within the cancer cells• Because of isotope like F we can detect them with PET CT
Cancer tracking
-
31
FDG uptake mechanism 32
https://www.researchgate.net/profile/Artem_Lebedev/publication/259010016/figure/fig2/AS:267481113690123@1440783875152/Figure-10-10-Proposed-mechanism-for-the-cellular-accumulation-of-18FFDG.png
-
32
which cancer we can use FDG?
FDG-PET include lymphoma, head and neck cancer,lung, colorectal cancer, breast cancer, esophageal cancer, melanoma, cervical cancer, thyroid cancer, and pancreatic cancer are “hot”
prostate cancer, neuroendocrine cancer,and well differentiated hepatocellular carcinoma, are often “cold” which limits the utility of FDG-PET
Cancer tracking
-
33
30-deoxy-30-18F-fluorothymidine (FLT)
• It uses for imaging cell proliferation
• Initial efforts focused on synthesizing analogs of thymidine, because thymidine is used byproliferating cells for DNA synthesis during the S-phaseof the cell cycle but, unlike other nucleosides, is not incorporated into RNA
• After injection, FLT enters the cell by nucleoside transporters and is trapped in the cytosol through phosphorylation
• Because FLT lacks a hydroxyl group at the 3′position, itis not incorporated into DNA , and its accumulationserves as a measure of cellular proliferation
Cancer tracking
-
34
The thymidine analog (1-[20-deoxy-20-18Ffluoro-beta-D_arabinofuranosyl]thymine) (FMAU)
• proliferation imaging probes• for studying bone metastases and genitourinary
malignancies
Cancer tracking
-
35
PET radiotracers have been developed to image hypoxia
2-nitroimidazoles, such as:
• 18F_fluoromisonidazole (FMISO)(research)
• 18F-fluoroetanidazole (FETA)
In solid tumors, hypoxia is associated with restrained proliferation, differentiation, apoptosis, and necrosis
nucleoside conjugates, such as
• 18F-fluoroazomycin arabinoside (FAZA)
• 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM)
Cancer tracking
-
36 PET radiotracers have been developed to image hypoxia
All of these agents undergo intracellular trapping at a rate
inversely proportional to intracellular oxygen concentration
Cancer tracking
-
Imaging Apoptosis
the detection of apoptosis can potentially be used to provide anearly indication of the success of therapy(in radiotherapy)
phosphatidylserine residues that normally reside on the intracellularmembrane surface but that are translocated to the extracellular surface during apoptosis
99mTc-annexin V is able to image apoptosis in vivo and topredict patient outcome after chemotherapy or radiationtherapy.
a radiolabeled protein with affinity to phosphatidylserine
37
Cancer tracking
-
The second class of imaging agents targets caspases
18F-ICMT-11 (a caspase-3- specific small molecule PET tracer based on the caspase inhibitor statin)
18F-CP18 (a pentapeptide-based PET tracer that is a substrate of caspase-3)
38
Cancer tracking
-
A third class of imaging agents
It detect plasma membrane depolarization
the most notable of these imaging agents is the PET tracer 18F-ML-10
39
Cancer tracking
-
cancer tracking with PET CT
40
2000-2004 2004-2008 2008-2012 2012-2016 2016-2017
Series1 2230 6230 12300 16300 3850
2230
6230
12300
16300
3850
-5000
0
5000
10000
15000
20000
Ar
tic
les
years
cancer tracking with PET CT
Cancer tracking
-
41
discussion
In vivo
https://www.ncbi.nlm.nih.gov/pubmed/25013808
-
Immunology , bioluminescence and
optical fluorescence imaging
-
43
Cancer tracking with immunology
The imaging modalities applied for T cell tracking in both preclinical and clinical studies include:
optical fluorescence/bioluminescenceimaging , computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET)
Cancer tracking
-
44
Cytotoxic T lymphocytes and cell labeling methods
However, in immunotherapy, cytotoxic T cells can be manipulated to recognize tumor-specific antigens When infused into a patient, the engineered T cells actively
attack and destroy the tumors displaying these antigens
There are two major principles in labeling the T cells for in vivo cell tracking:
direct and indirect labeling
Cancer tracking
-
45
Cytotoxic T lymphocytes and cell labeling methods
Direct labeling
generally requires isolation and ex vivoexpansion of the T cells from the subject, followed bylabeling with a proper imaging probe in vitro and injection of these cells into the subject
indirect labeling involves genetic engineering of the T cells by transfecting
them with a reporter gene that encodes an enzyme or transporter, which can utilize the designated imaging probe as a substrate and allow for visualization and tracking of these T cells over time
Cancer tracking
-
46
Tracking T cells by optical fluorescence and bioluminescence imaging
In optical fluorescence imaging, T cells are labeled by fluorophores, fluorescent proteins, or quantum dots
The fluorophores are usually near infrared (NIR) fluorescent dyes, such as indocyanine green
labeled cells could be detected by flow cytometry
the labeled CTLs and the tumor cells could be detected by confocal intravital microscopy
The optical fluorescence imaging with fluorophores usually adopts a direct labeling strategy, while imaging with fluorescent proteinsinvolves an indirect method
Quantum dots (QDs) are a class of semiconductor nanocrystals (2-6 nm in size) that have broad excitation spectra
Direct labeling methods
-
47
Tracking T cells by optical fluorescence and bioluminescence imaging
Indirect labeling methods
Bioluminescence optical imaging is in principle distinct from the fluorescence imaging and involves an indirect labeling strategy.
Indirect labeling by fluorescent proteins. Fluorescent proteins, such as green fluorescent protein (GFP)
and red fluorescent protein (RFP), are also used to tag the T cells
A DNA construct carrying a coding sequence for GFP or RFPis introduced into the cell
It has become a powerful means to probe the mechanisms for biological processes in vitro and in preclinical studies.
Cancer tracking
-
48
Tracking T cells by optical fluorescence and bioluminescence imaging
Indirect labeling methods
Indirect labeling by bioluminescent agents:
a luciferase enzyme is expressed in the cell; when its substrate luciferin is introduced, luciferase can catalyze the oxidation of luciferin in the presence of ATP and oxygen
The reaction emits photons and only living cells can produce signals
produced a transgenic bioluminescence mouse model from which they isolated the T cells that constantly expressed luciferase
The BLI results clearly showed these adoptively transferred T cells homed to the antigen-positive tumors.
Cancer tracking
-
cancer tracking with immunology
49
2000-2004 2004-2008 2008-2012 2012-2016 2016-2017
Series1 5670 10600 15000 17700 6270
5670
10600
15000
17700
6270
0
5000
10000
15000
20000
25000A
rtic
les
years
cancer tracking with immunology
-
50
1500
3100
6060
8610
2510
0
2000
4000
6000
8000
10000
12000
Nu
mb
er
of
ar
tic
les
Years
Bioluminescence and optical fluorescence imaging
-
51
Discussion
In vivo
-
52
Discussion
In vivo In vitro
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781579/
55
-
53
discussion
in vivo
https://www.ncbi.nlm.nih.gov/pubmed/25157278 43
-
referencesMri references
1.Ethel J. Ngen and Dmitri Artemov. Advances in Monitoring Cell-Based Therapies with Magnetic Resonance Imaging: Future Perspectives.received: 26 October 2016; Accepted: 10 January 2017; Published: 19 January 2017
2. Yusri D Heryanto1, Arifudin Achmad1,2,3, Ayako Taketomi-Takahashi1, Yoshito Tsushima Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine,Maebashi, Gunma, Japan; Human Research Cultivation Center, Gunma University, Kiryu, Gunma, Japan; Department of Radiology, Faculty of Medicine, Gadjah Mada University, Yogyakarta, Indonesia . In vivo molecular imaging of cancer stem cells Received August 27, 2014; Accepted September 5, 2014; Epub December 15, 2014; Published January 1, 2015
54
-
Mri references
3. Daniel Spira, MD, Fritz Schick, MD, PhD, Ru¨ diger Bantleon, PhD, Hartwig Wolburg, PhD and Benjamin Wiesinger, MD, Gerd G , Department of Diagnostic and Interventional Radiology, Universita¨tsklinikum Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg Department of Diagnostic and Interventional Radiology, Eberhard- Karls-University Tu¨bingen, Hoppe- Seyler -Str. 3, 72076 Tu¨bingen, Germany Institute of Pathology and Neuropathology, Eberhard- Karls-University . Labeling Human Melanoma Cells With SPIO: In Vitro Observations. Submitted: 29/11/2014. Revised: 16/11/2015. Accepted: 20/11/2015.
4. Christian Weis, Fabian Blank,Adrian West,Gregory lack,RobertWoodward,MatthewR.J.Carroll,Astrid Mainka,Ren_e artmann,Andreas Brandl,Heiko Bruns,Elizabeth Hallam,Jeremy Shaw,John Murphy,Wey Yang Katerina E. Aifantis,Rose Amal,Mike House,Tim St. Pierre,and Ben Fabry . Labeling of cancer cells with magnetic nanoparticles for magnetic resonance imaging. Published online 28 June 2013 in Wiley Online library(wileyonlinelibrary.com).
5. Paolo E. Porporato Pierre Danhier, Géraldine De Preter, Julie Magat, Quentin Godechal Pierre Sonveaux, Bénédicte F. Jordan, Olivier Feron and Bernard Gallez. Multimodal cell tracking of a spontaneous metastasis model: comparison between MRI , electron paramagnetic resonance and Bioluminescence received: 2 January 2013,Revised: 3 May 2013,Accepted: 3 June 2013,Published
55
-
Pet CT/MRI References
6. Kim JS1, Kim YH, Kim JH, Kang KW, Tae EL, Youn H, Kim D, Kim SK, Kwon JT, Cho MH, Lee YS, Jeong JM, Chung JK, Lee DS. Cancer. Development and in vivo imaging of a PET/MRI Nano probe with enhanced NIR fluorescence by dye encapsulation. 2014 Jun 19
7. Haubner R1, Maschauer S2, Prante O2PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments. Epub 2014 Jun 11
8. Danhier P1, De Preter G, Magat J, Godechal Q, Porporato PE, Jordan BF, Feron O, Sonveaux P, Gallez B. Multimodal cell tracking of a spontaneous metastasis model: comparison between MRI, electron paramagnetic resonance and bioluminescence. 2014 Mar-Apr
9. Farwell MD1, Pryma DA, Mankoff DA. PET/CT imaging in cancer: current applications and future directions. Cancer. 2014 Nov
56
https://www.ncbi.nlm.nih.gov/pubmed/?term=Kim JS[Author]&cauthor=true&cauthor_uid=22175235https://www.ncbi.nlm.nih.gov/pubmed/?term=Kim YH[Author]&cauthor=true&cauthor_uid=22175235https://www.ncbi.nlm.nih.gov/pubmed/?term=Kim JH[Author]&cauthor=true&cauthor_uid=22175235https://www.ncbi.nlm.nih.gov/pubmed/?term=Kang KW[Author]&cauthor=true&cauthor_uid=22175235https://www.ncbi.nlm.nih.gov/pubmed/?term=Tae EL[Author]&cauthor=true&cauthor_uid=22175235https://www.ncbi.nlm.nih.gov/pubmed/?term=Youn H[Author]&cauthor=true&cauthor_uid=22175235https://www.ncbi.nlm.nih.gov/pubmed/?term=Kim D[Author]&cauthor=true&cauthor_uid=22175235https://www.ncbi.nlm.nih.gov/pubmed/?term=Kim SK[Author]&cauthor=true&cauthor_uid=22175235https://www.ncbi.nlm.nih.gov/pubmed/?term=Kwon JT[Author]&cauthor=true&cauthor_uid=22175235https://www.ncbi.nlm.nih.gov/pubmed/?term=Cho MH[Author]&cauthor=true&cauthor_uid=22175235https://www.ncbi.nlm.nih.gov/pubmed/?term=Lee YS[Author]&cauthor=true&cauthor_uid=22175235https://www.ncbi.nlm.nih.gov/pubmed/?term=Jeong JM[Author]&cauthor=true&cauthor_uid=22175235https://www.ncbi.nlm.nih.gov/pubmed/?term=Chung JK[Author]&cauthor=true&cauthor_uid=22175235https://www.ncbi.nlm.nih.gov/pubmed/?term=Lee DS[Author]&cauthor=true&cauthor_uid=22175235https://www.ncbi.nlm.nih.gov/pubmed/24947987https://www.ncbi.nlm.nih.gov/pubmed/?term=Haubner R[Author]&cauthor=true&cauthor_uid=25013808https://www.ncbi.nlm.nih.gov/pubmed/?term=Maschauer S[Author]&cauthor=true&cauthor_uid=25013808https://www.ncbi.nlm.nih.gov/pubmed/?term=Prante O[Author]&cauthor=true&cauthor_uid=25013808https://www.ncbi.nlm.nih.gov/pubmed/?term=Danhier P[Author]&cauthor=true&cauthor_uid=24523059https://www.ncbi.nlm.nih.gov/pubmed/?term=De Preter G[Author]&cauthor=true&cauthor_uid=24523059https://www.ncbi.nlm.nih.gov/pubmed/?term=Magat J[Author]&cauthor=true&cauthor_uid=24523059https://www.ncbi.nlm.nih.gov/pubmed/?term=Godechal Q[Author]&cauthor=true&cauthor_uid=24523059https://www.ncbi.nlm.nih.gov/pubmed/?term=Porporato PE[Author]&cauthor=true&cauthor_uid=24523059https://www.ncbi.nlm.nih.gov/pubmed/?term=Jordan BF[Author]&cauthor=true&cauthor_uid=24523059https://www.ncbi.nlm.nih.gov/pubmed/?term=Feron O[Author]&cauthor=true&cauthor_uid=24523059https://www.ncbi.nlm.nih.gov/pubmed/?term=Sonveaux P[Author]&cauthor=true&cauthor_uid=24523059https://www.ncbi.nlm.nih.gov/pubmed/?term=Gallez B[Author]&cauthor=true&cauthor_uid=24523059https://www.ncbi.nlm.nih.gov/pubmed/?term=Farwell MD[Author]&cauthor=true&cauthor_uid=24947987https://www.ncbi.nlm.nih.gov/pubmed/?term=Pryma DA[Author]&cauthor=true&cauthor_uid=24947987https://www.ncbi.nlm.nih.gov/pubmed/?term=Mankoff DA[Author]&cauthor=true&cauthor_uid=24947987https://www.ncbi.nlm.nih.gov/pubmed/24947987
-
Immunology and bioluminescence and optical imaging references
10. Zhiyi Liu and Zheng Li. Molecular Imaging in Tracking Tumor-Specific Cytotoxic T Lymphocytes (CTLs) . Theranostics 2014, Vol. 4, Issue 10
11.Judith M. Runnels, Alicia L. Carlson, Costas Pitsillides, Brian Thompson, Juwell Wu, Joel A. Spencer, John M. J. Kohler,Abdel Kareem Azab, Anne Sophie Moreau, Scott J. Rodig, Andrew L. Kung, Kenneth C. Anderson,Irene M. Ghobrial, and Charles P.Lin,Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy published online 2011 Jan 11. doi:10.1117/1.3520571
12. Aaron J. Clark Shayan Fakurnejad, Quanhong Ma, Rintaro Hashizume, Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma,jovevideo.com, 1/15/2016
57
-
Thanks for your attention
58